Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in
Advertisement

Alterity Therapeutics Limited ATHE

Set alert

Price alert · ATHE

All alert types
2.16 USD -0.07 -3.29%

At close · Oct 30

2.12 -0.04 -1.85%

After hours · Oct 30, 4:00 PM ET

Bid
2.12 × 1
Ask
2.24 × 1
2.11 Day range 2.12
2.01 52-week range 5.89
YTD
-29.87%
1 year
-53.04%
Open
2.12
Prev close
2.23
Mkt cap
41.24M
Vol
8.89K
Avg vol
20.46K
EPS
-0.90
P/E
0.00
Div yield
0.00%
More statistics
Low
2.11
High
2.12
Forward P/E
-27.22
Beta
0.68
Short ratio
0.04
Inst. own
1.28%
Dividend
0.00
Ex-div date
50-d avg
1.48
200-d avg
1.67
1y target
8.00

1D chart

Chart tools
Interval
1m5m15m30m

Key statistics

Financials
Market cap
21.42M
Enterprise value
11.69B
Trailing P/E
0.00
Forward P/E
-27.22
PEG ratio
0.00
Price / sales
5.33
Price / book
816.67
EPS (TTM)
-4.21
Beta
0.68
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
4.02M
Revenue growth
38.40%
Free cash flow
-5.36M
Total cash
12.64M
Total debt
159.04K
Return on equity
-104.47%
Shares outstanding
8.74M
Short % of float
0.02%
50-day average
1.48
200-day average
1.67

Analyst view

Consensus: buy

Buy
Price target (mean) 8.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy0
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
ATHE Revenue — annual 3.61M
2011-FY 20112012-FY 20122013-FY 20132014-FY 20142015-FY 20152016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 20252026-FY 2026
ATHE Net income — annual -23.40M
2011-FY 20112012-FY 20122013-FY 20132014-FY 20142015-FY 20152016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 20252026-FY 2026
ATHE EPS — annual -1.33
2011-FY 20112012-FY 20122013-FY 20132014-FY 20142015-FY 20152016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 20252026-FY 2026

Upgrades / downgrades

ATHE analyst upgrades and downgrades
DateFirmActionFromTo
Dec 12, 2024Maxim Groupinit—Buy
Mar 7, 2024BenchmarkreitSpeculative BuySpeculative Buy
Jun 5, 2023Ladenburg ThalmannmainBuyBuy

About Alterity Therapeutics Limited

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Sector
Healthcare
Industry
Biotechnology
Country
Australia
Website
alteritytherapeutics.com

News

All news

Your note

Sign in to keep a note on ATHE — it syncs with the Stock Master app.

Institution ownership

ATHE institution ownership
Holder% heldSharesValueReported
Morgan Stanley0.50%44,501109.03KSep 29, 2024
HB Wealth Management, LLC0.27%23,78358.27KSep 29, 2024
Susquehanna International Group, LLP0.16%13,93234.13KSep 29, 2024
UBS Group AG0.14%12,68531.08KSep 29, 2024
Citadel Advisors Llc0.13%11,48828.14KSep 29, 2024
Twin Lakes Capital Management, LLC0.07%5,92514.52KSep 29, 2024

Fund ownership

ATHE fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.01%1,1552.83KOct 30, 2024

Splits

ATHE stock splits
DateRatio
Jan 9, 20231:10
Mar 24, 20161:6
Advertisement